Recent Updates
Recently added Catalysts
NTRA Positive Sentiment

Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM

Friday, September 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Natera, Inc. has unveiled significant findings at the IASLC 2026 World Conference on Lung Cancer, showcasing the largest molecular residual disease (MRD) dataset in lung cancer history. The analysis involved 1,129 patients and highlighted the strong prognostic value of SignateraTM. This presentation underscores Natera's leadership in precision medicine.

Market Sentiment Analysis

POSITIVE FACTORS

  • Largest MRD dataset presented in lung cancer.
  • Strong prognostic value demonstrated for SignateraTM.
  • Collaboration with notable researchers enhances credibility.
  • Presentation at a major conference boosts visibility.

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. Natera and its collaborators presented four abstracts, including two oral presentations. A mini-oral presentation featured the largest molecular residual disease (MRD) dataset ever presented in lung cancer. This analysis of 1,129 patients with rese

Frequently Asked Questions

What is SignateraTM?

SignateraTM is a precision medicine tool developed by Natera for monitoring molecular residual disease.

Where was the MRD study presented?

The study was presented at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea.

How many patients were included in the MRD dataset?

The MRD dataset included 1,129 patients, marking a significant contribution to lung cancer research.

What does MRD stand for?

MRD stands for molecular residual disease, which refers to the small number of cancer cells that may remain after treatment.

ShareAdd on Google
Tags: NTRA Viatris Investor Conferences Healthcare Natera SignateraTM lung cancer MRD dataset precision medicine
Last updated: Sep 18, 2026

Biotech snapshot

Cash runway
$1092M liquidity · $0M/mo burn
Low dilution risk